Brief: Humacyte Submits Biologics License Application To US FDA Seeking Approval Of Human Acellular Vessel For The Treatment Of Vascular Trauma
12/12/2023 13:35
Dec 12 (Reuters) - Humacyte Inc HUMA.O :
* HUMACYTE SUBMITS BIOLOGICS LICENSE APPLICATION (BLA) TO
U.S. FDA
SEEKING APPROVAL OF HUMAN ACELLULAR VESSEL™ (HAV™) FOR THE
TREATMENT OF VASCULAR TRAUMA
Source text for Eikon: ID:nGNX3K50Bx
Further company coverage: HUMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Humacyte
See all newsBrief: Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Humacyte falls after wider-than-expected quarterly loss
Humacyte Inc reports results for the quarter ended June 30 - Earnings Summary